dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2021-06-25T10:13:52Z
dc.date.accessioned2022-12-19T22:03:55Z
dc.date.available2021-06-25T10:13:52Z
dc.date.available2022-12-19T22:03:55Z
dc.date.created2021-06-25T10:13:52Z
dc.date.issued2019-01-01
dc.identifierPrecision Medicine for Investigators, Practitioners and Providers, p. 71-82.
dc.identifierhttp://hdl.handle.net/11449/205350
dc.identifier10.1016/B978-0-12-819178-1.00008-3
dc.identifier2-s2.0-85093476402
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5385948
dc.description.abstractA vast microbial community lives on and within the human body. Recent advances in microbiome studies have shown how some living bacteria can positively influence human health. The findings have raised interest in engineering indigenous human microbes to produce and deliver vaccines, drugs, and immunomodulators directly in or on the patient’s body, targeting a range of human diseases. Engineered living microorganisms are the next generation of therapeutics, programmed to diagnose and treat infections, tumors, metabolic disorders, and neurological diseases. This disruptive treatment approach is now nearing the clinic. This chapter will cover the most recent synthetic biology tools and approaches for engineering microbes as living therapeutics. Moreover, some technical and safety issues will be addressed.
dc.languageeng
dc.relationPrecision Medicine for Investigators, Practitioners and Providers
dc.sourceScopus
dc.subjectDesigner probiotics
dc.subjectDrug delivery
dc.subjectEngineered microorganisms
dc.subjectHuman microbiome
dc.subjectLiving therapeutics
dc.subjectSynthetic biology
dc.titleEngineering microbial living therapeutics
dc.typeCapítulos de libros


Este ítem pertenece a la siguiente institución